Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients

European Journal of Haematology

Volumn 82, Issue 3, 2009, Pages 240-241

  Mangiacavalli, Silvia ^a,b   Pica, GianMatteo ^a   Varettoni, Marzia ^a   Lazzarino, Mario ^a   Corso, Alessandro ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; FOTEMUSTINE; THALIDOMIDE;

ADULT; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; LETTER; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RECURRENCE;

EID: 58849114126     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01184.x     Document Type: Letter

References (6)

1. Reece DE, Management of multiple myeloma: the changing landscape. Blood Rev. 2007 21 : 301 14. Epub 2007 Aug 29
2. Attal M, Harousseau JL. Role of autologous stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol. 2007 20 : 747 59.
3. Facon T, Darre S. Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Best Pract Res Clin Haematol. 2007 20 : 737 46. Review.
4. De Rossi A, et al. Focus on Fotemustine. J Exp Clin Cancer Res 2006 25 : 461 8.
5. Dumontet C, et al. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol 2003 14 : 615 22.
6. Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 20 : 1467 73.